Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228676 | 0.85 | DPP4 (0.41) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL5229207 | 0.82 | DPP4 (0.53) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL5230427 | 0.80 | DPP4 (0.38) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL5229332 | 0.80 | DPP4 (0.46) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL5228044 | 0.80 | TACR1 (0.39) | DPP4DPP7DPP9DPP8NR1H2 | |
| SCHEMBL5228855 | 0.79 | DPP4 (0.49) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL5233907 | 0.73 | DPP4 (0.54) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL5228869 | 0.73 | DPP4 (0.54) | DPP4DPP7DPP9DPP8ALDH1A1 | |
| SCHEMBL489369 | 0.67 | NR1H2 (0.39) | GPR119NR1H2NR1H3 | |
| SCHEMBL489371 | 0.67 | NR1H2 (0.39) | GPR119NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554280-B1 | ANTIDIABETIC BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS | MERCK & CO INC (US) | 2007-08-15 | — | — | EP | disclosed |